KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
Astellas Pharma Inc
Tizona Therapeutics, Inc
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
BioAtla, Inc.
Pfizer
Sanofi
Blokhin's Russian Cancer Research Center
University of California, San Diego
Celgene
GlaxoSmithKline
Al-Azhar University
Biond Biologics
Fox Chase Cancer Center
Eisai Inc.
NKGen Biotech, Inc.
Eli Lilly and Company
M.D. Anderson Cancer Center
Sichuan Cancer Hospital and Research Institute
University of Chicago
Bayer
Eli Lilly and Company
Novartis
Merck Sharp & Dohme LLC
Eli Lilly and Company
Eli Lilly and Company
AbbVie
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Pittsburgh
University of Kansas Medical Center
Merck KGaA, Darmstadt, Germany
University of Pittsburgh
Fox Chase Cancer Center
University Hospital, Ghent
Hoffmann-La Roche
Eli Lilly and Company
Regeneron Pharmaceuticals
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
National University Hospital, Singapore
University of California, San Francisco
Austrian Breast & Colorectal Cancer Study Group
Eli Lilly and Company
Eli Lilly and Company
Harrison Clinical Research